Evaluation of calpain T-cell epitopes as vaccine candidates against experimental *Leishmania major* infection: a pilot study

Reham Brakat 1 · Amal Mahmoud 2 · Eman Abd El Gayed 1 · Shaimaa Soliman 1 · Shaimaa Sharaf-El-Deen 1

Received: 26 June 2022 / Accepted: 1 September 2022 / Published online: 14 September 2022
© The Author(s) 2022

**Keywords** Leishmania major · Vaccine · Calpain · T-Cell epitope · Memory cells

**Introduction**

Leishmaniiasis is a neglected tropical disease caused by *Leishmania (L.)* species. Infection usually occurs due to the bite of an infected sand fly. Leishmaniiasis manifests in a variety of pathological forms depending on the infecting species, ranging from fatal systemic disease (visceral leishmaniasis) to localized skin ulcers (cutaneous leishmaniasis [CL]), which is the most common form (Kaye et al. 2020). According to the World Health Organization, 92 countries are considered endemic for CL or have previously reported cases, with more than one billion people inhabitants at risk of infection. The number of new cases reported annually is more than one million (https://www.who.int/leishmaniasis/en/).

The CL ulcers commonly form on exposed skin areas of the body and usually heal spontaneously, leaving permanent disfiguring scars. This disfigurement is a cause of psychological distress, social stigma, and decreased quality of life. When CL occurs in individuals from nonendemic areas, such as travelers and military personnel, the problem becomes more complicated because it is frequently misdiagnosed as a form of skin ulcer. Thus, the patient loses the opportunity to get proper treatment at the appropriate time (Ennes-Vidal et al. 2017; Bilgic-Temel et al. 2019).

Control of CL depends primarily on chemotherapeutic agents that have many side effects and may not be effective against the emergence of resistant strains. For this reason, vaccination is a logical step toward the proper management of CL (Rabienia et al. 2020). Due to the lifelong immunity that results from natural infection, developing an effective vaccine for the global eradication of CL is an attainable goal (Gillespie et al. 2016; Zhang et al. 2020).

Epitope-based vaccines have shown promising results among various vaccine approaches. They are based on short antigenic epitopes that can elicit the desired immune response and stimulate specific CD4+ and CD8+ T-cell responses, which are crucial for clearing *Leishmania major* infection (Skwarczynski and Toth 2016; Bordbar et al. 2020). In terms of ease of manufacture, low cost, absence of potentially harmful substances, reduced antigen complexity, and stability, epitope-based vaccines outperform other vaccination strategies. One of the primary considerations in selecting a target gene is the ability of its protein product to elicit a robust immune response (Gershoni et al. 2007; Skwarczynski and Toth 2016; De Brito et al. 2018).

Calpains are specific calcium-dependent cysteine proteases expressed by several parasites, such as *Trypanosomes, Leishmania, Schistosomes,* and *Plasmodium falciparum* (Kumar and Ahmad 2017). In *L. major*, 27 calpain sequences have been identified, which are thought to be involved in essential processes (Ersfeld et al. 2005; Branquinha et al. 2013). Calpain upregulation has also been associated with drug resistance and virulence in *Leishmania* (Ennes-Vidal et al. 2017). Therefore, they were tested as targets for vaccine and drug development. The therapeutic efficacy of calpain inhibitors was found to be satisfactory and reduced promastigote proliferation and the number of intracellular amastigotes (De Souza Araújo et al. 2018).

To our knowledge, this is the first published study evaluating calpain peptides as vaccine candidates for protection against *L. major*.

In this study, we used immunoinformatics tools to design six T-cell epitopes from *L. major* calpains directed at CD4+ or CD8+ T-cells. In addition, we aimed to evaluate the protective effects of these epitopes adsorbed to the Imjet alum adjuvant and the mechanism of this protection in BALB/c mice infected with *L. major* promastigotes.
**Methods**

**Ethics statement**

Mice were kept under standard breeding conditions in the animal house of Theodor Bilharz Research Institute (TBRI), Giza, Egypt. The breeding room was air-conditioned at 20–22 °C, and mice were fed a commercial pellet diet. All the study procedures were performed in accordance with the international ethical guidelines approved by the institutional ethical committee of TBRI and Faculty of Medicine, Menofia University (ethics number, 9/2021PARA20).

**Epitope prediction**

The FASTA-formatted amino acid sequences of calpain-like cysteine peptidases were retrieved from the National Center for Biotechnology Information (NCBI) database. The VaxiJen v2.0 server (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) was used to predict the sequence of the most antigenic calpain-like cysteine peptidase with a threshold of 0.5 (Doytchinova and Flower 2007). T-cell epitopes were predicted using IEDB (http://tools.iedb.org/mhci/ and http://tools.iedb.org/mhcii/), with an IC50 binding value <200 and <1000 for MHC-I and MHC-II, respectively. The conservancy (http://tools.iedb.org/conservancy/), with sequence identity threshold 100%, and immunogenicity (http://tools.iedb.org/immunogenicity/) prediction tools of IEDB were used for epitope conservancy and immunogenicity predictions, respectively (Li et al. 2008; Calis et al. 2013). The population coverage tool (http://tools.iedb.org/population/) was used to analyze the population coverage of the predicted epitopes and their respective MHC HLA-binding alleles (Dimitrov et al. 2014a). Allergenicity was predicted using AllerTOP v. 2.0 (https://www.ddg-pharmfac.net/AllerTOP/index.html) (Dimitrov et al. 2014a) and AllergenFP 1.0 (http://www.ddg-pharmfac.net/AllergenFP/) (Dimitrov et al. 2014b). Peptide toxicity was predicted using ToxinPred (http://www.imtech.res.in/raghava/toxinpred/) (Gupta et al. 2013). BepiPred-2.0, with a threshold of 0.5 (https://services.healthtech.dtu.dk/service.php?BepiPred-2.0) (Jespersen et al. 2017), and LBtope, with % probability threshold of 60% (http://crdd.osdd.net/raghava/lbtope/) (Singh et al. 2013), were used to identify B-cells with the most antigenic proteins. The designated short peptides were synthesized by GenScript, USA.

**Animals and study design**

A total of 115 inbred pathogen-free male BALB/c mice (6–8 weeks, 18–20 gm) were randomly categorized into three groups. Group I (GI; 10 mice) served as the uninfected control. Group II (GII; 15 mice) served as the *L. major*-infected control. Group III (GIII; 90 mice) was the T-cell epitope-immunized group. Based on epitope type, GIII was further classified into subgroups A–F. Each subgroup included 15 mice.

**Immunization protocol**

GIII mice were subcutaneously injected with 100 µg of the synthetic peptide in the right footpad. The immunization dose was prepared by dissolving 100 µg of the synthetic peptide in 100 µL of phosphate buffered saline (PBS) (Spitzer et al. 1999), then adding 100 µL of Imject Alum (an aqueous solution of aluminum hydroxide and magnesium hydroxide plus inactive stabilizers; Thermo Fisher Scientific, USA), and vortexing the solution for 30 min to allow the Imject Alum to effectively adsorb the antigen. A similar booster dose was administered 3 weeks later. The synthetic peptides received by subgroups A–F are summarized in Table 1. GI mice were subcutaneously injected with two doses of 100 µL of Imject Alum alone with 3-week interval.

**Challenge with *L. major***

Three weeks after the booster dose, GII and GIII mice were subcutaneously injected with *2 × 10^6* *L. major* promastigotes (in 50 µL PBS) (MHOM/IL/81/FEBNI) into the left footpad. This strain was obtained from the Faculty of Veterinary Medicine, Cairo University, Egypt, where the infection was maintained in laboratory bred BALB/c mice. Promastigotes were harvested from the Novy–MacNeal–Nicolle medium during the stationary phase.

**Evaluation of skin lesions**

Two weeks after *L. major* challenge, the sizes of the developing footpad swellings were measured weekly using digital calipers until week 8 post infection (p.i.). The thickness and width of the left and right footpads were measured in

| Subgroup name | Targeted lymphocyte | Synthesized peptide |
|---------------|---------------------|---------------------|
| A             | CD4+                | NERARELAWATLAAD     |
| B             | CD4+                | DPAKHAGAIAHLESE     |
| C             | CD4+                | TQHPVLLRLIVTK       |
| D             | CD8+                | ARELAWATL           |
| E             | CD8+                | KHAGAIAHL           |
| F             | CD8+                | LLRLIVT           |
millimeters, and lesion size was calculated according to the following equation (Shermeh et al. 2021).

\[
\text{lesion size} = (\text{left foodpad thickness} + \text{left footpad width}) - (\text{right foodpad thickness} + \text{right footpad width})
\]

Outcome measures

Mice groups were assessed by TCM flowcytometry (3 weeks after the booster immunization; Zhang et al. 2013), parasite cycle threshold (CT) (Tupperwar et al. 2008), Th1 [IgG2a and IFN-γ] and Th2 biomarkers [IgG1 and IL-4] (4 weeks p.i.), and lesion size measurement (from week 2 to 8 p.i.; Shermeh et al. 2021).

Flow cytometric analysis of TCM lymphocytes

Three weeks after the booster dose, five mice from each group (except 3 from GI) were euthanized by cervical dislocation. Popliteal lymph nodes were dissected and pooled in RPMI 1640 medium (Sigma-Aldrich, USA) and pressed through a 70-µm cell strainer on top of a 15-mL tube with a sterile 3-mL syringe plunger. The lymph nodes were frequently flushed with 6 mL RPMI, containing 10% fetal bovine serum. The collected cells were centrifuged at 1000 × g, 5 min. After the supernatant was discarded, the pellet was resuspended in 500 µL PBS and refiltered using a 30-µm cell strainer into a new 15-mL tube to remove coagulated cells. Then, we performed flowcytometric analysis of T central memory (TCM) cells (Haubruck et al. 2020). TCM cells of popliteal lymph nodes were labeled with anti-CD4, CD44, and CD62L monoclonal antibodies (Abcam, USA). Cell percentage was determined using the fluorescence-activated cell sorter Calibur system (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) (Zhang et al. 2013).

Quantification of parasitic burden using real-time polymerase chain reaction (RT-PCR)

Four weeks p.i., 5 mice from each group (except 3 from GI) were decapitated. Popliteal lymph nodes were dissected and frozen to measure the parasitic burden using RT-PCR. Genomic DNA was extracted from 10 mg frozen lymph nodes of each mouse using the JET Genomic DNA Purification Mini Kit (Thermo Scientific, EU/Lithuania). The extracted DNA was stored at −20 °C until use. Primer specificity was confirmed using Primer BLAST. Each primer (25 nmole) was dissolved in 250 μL RNase-free water to obtain a solution of 100 μmol/L as a final concentration. The following primers were used: forward, 5'-GGG GTT GGT GTA AAA TAG GG-3' and reverse 5'-TTT GAA CCG GAT TTC TG-3' (Miland, TX). A total volume of 20 μL was used for the RT-PCR reaction, including 10 μL SYBR Green 2×Quanti-Tect PCR Master Mix (Thermo Fisher Scientific, Waltham, USA), 3 μL DNA, 1 μL forward primer, 1 μL reverse primer, and 5 μL RNase-free H2O. The reaction mix was incubated at 95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C for 10 s, annealing at 60 °C for 15 s, and extension at 72 °C for 20 s. Data analysis was performed using the Applied Biosystems 7500 software version 2.0.1 in the Central Lab, Faculty of Medicine, Menoufia University. Fluorescence was measured in the green channel, and data were collected during the extension step. CT values were individually calculated with an internal software using a manual threshold setting of 0.2 and activating the “dynamic tube” and “ignore first 10 cycles” functions. After each run, melt-curve analysis was performed to match amplicons with positive control melt-curve peaks and confirm specificity. CT value in the lymph node was inversely proportional to the amount of DNA detected by RT-PCR.

Assessment of IFN-γ and IL-4

A part of the popliteal lymph node obtained 4 weeks p.i. was homogenized according to Belkhelfa-Slimani and Djerdjouri (2018). Briefly, lymph nodes were homogenized in 50 mM ice-cold phosphate buffer (pH = 7.2), containing 0.5% Triton X-100 (Sigma-Aldrich, USA), and freeze-thawed three times. Homogenates were centrifuged at 10,000 × g for 10 min at 4 °C. Supernatants were stored at −70 °C. Levels of IFN-γ and IL-4 in the supernatant of the lymph node homogenate were measured using solid-phase sandwich ELISA (Life Technologies Corporation, Thermo Fisher, USA for IFN-γ and Abcam, USA for IL-4). The procedures were performed according to the manufacturer’s protocol.

Assessment of antibody response (IgG2a and IgG1)

Four weeks p.i., serum of decapitated mice was used to measure IgG2a and IgG1 levels. Stationary promastigotes suspended in PBS underwent three cycles of freezing and thawing and then centrifuged at 12,000×g for 15 min. The supernatant containing the soluble Leishmania antigen (SLA) was collected, and the protein concentration was measured by colorimetry, adjusted to 1.3 gm/dl, and stored at −70 °C until use (Solana et al. 2017). A titration curve was constructed, and the optimum concentration of SLA was found to be 200 ng/well. Then, 96-well microtiter plates were coated with SLA and incubated at 37 °C for 4 h. The plates were washed and blocked overnight at 4 °C with 200 μL of 10% fetal calf serum in PBS-Tween per well. Serum samples were diluted to 1:100 with PBS-Tween-10% fetal calf serum.
and applied to plates in twofold serial dilutions. Plates were incubated at 37 °C for 4 h, washed, and incubated with 1:2000 dilution of horseradish peroxidase-conjugated goat anti-mouse IgG2a or IgG1 antibodies (Zymed Laboratories Inc., USA) for 2 h at 37 °C. Detection was performed using the colorimetric substrate 3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich). Optical density (OD) was read at 450 nm.

**Statistical analysis**

Statistical analysis was performed using the SPSS statistical package, version 26 (SPSS Inc. Released 2019. IBM SPSS statistics for windows, version 23.0, Armonk, NY: IBM Corp.). Variables were expressed as the mean (x̄), standard deviation, median, and range. Analysis of variance (ANOVA) (with homogeneity testing) was used for comparison of quantitative variables between more than two groups of normally distributed data with Tukey’s post hoc test. The Kruskal–Wallis test was used for comparison of quantitative variables between more than two groups of abnormally distributed data with the Tamhane post hoc test. A two-sided p value of <0.05 was considered statistically significant.

**Results**

**Calpain-like cysteine peptidase epitope prediction**

The query for calpain-like cysteine peptidase XP_003721857.1 (5,358 aa) was retrieved from UniProt and used for database search using BLASTp. A total of 100 hits (identity 34.12–91.52%) in the NCBI database, eight highly similar sequences (identity 76.25–91.52%), and XP_003721857.1 were used. Among all calpain-like cysteine peptidase sequences, the protein sequence with GenBank ID > TPP47601.1 had the highest antigenic score of 0.5901. This protein was used for further analysis (Fig. 1).

Of the 203 predicted CD8 + T-cell epitopes, we identified three (ARELAWATL, KHAGAIAHL, and LLRLIVTK) that were characterized by high antigenicity and immunogenicity scores, conservancy, and allergenicity (Table 2). These epitopes were used to predict MHC-II alleles and their respective peptides or CD4 + T-cell epitopes (Table 2).

**Effects of epitopes on TCM cells**

The highest percentage of TCM cells was detected with the CD4 + lymphocyte-directed TQHPVLLRRLIVTKE epitope used in subgroup C (14.20% ± 0.73%). The CD8 + lymphocyte-directed epitope, KHAGAIAHL used for subgroup E, also elicited a marked elevation of TCM cells (6.92 ± 0.95) and ranked second to subgroup C, with a statistically significant difference between both subgroups (p < 0.001). TCM cell percentages of the remaining subgroups were markedly lower than subgroups C and E, with statistically significant differences (p < 0.01). The lowest percentage was recorded in subgroup A (0.02% ± 0.01%) (Fig. 2).

**Disease progression and lesion size**

All the vaccinated mice showed milder disease progression compared with the infected controls, except those in subgroup A. The slowest disease progression
and smallest lesion size throughout the study were detected in subgroup C mice, followed by subgroup E mice, with statistically significant differences compared with the other subgroups (p < 0.05). The progression of the disease in subgroup A was not much better than that in the infected control. The difference between both groups was not statistically significant (p > 0.05) (Fig. 3a).

**Effects of epitopes on parasite burden**

Subgroup C, immunized with the CD4+ lymphocyte-directed epitope TQHPVLLRRLIVTKE, had the highest CT value (37.70 ± 0.89), suggesting lowest parasite burden with a percentage of change (PC) = 138.48%. Differences between subgroup C and all other subgroups were statistically significant (p < 0.001). Subgroups E (27.07 ± 0.39; PC = 71.21%) and B (27.24 ± 0.04; PC = 72.27%), which received CD8+ and CD4+ lymphocyte-directed epitopes, KHAGAIAHL and DPAKHAGAIAHLESE, respectively, were ranked second (p = 1.00). Subgroup A was ranked last (14.24 ± 0.59; PC = −8.66). In contrast to that of the other immunized subgroups, the CT of subgroup A was not statistically different from that of the infected control group II (15.82 ± 0.34) (p = 0.093) (Fig. 3b).

**Effects of epitopes on levels of IFN-γ and IL-4**

In contrast to the parasite burden, the highest level of IFN-γ was recorded in subgroup C (517.60 ± 3.64 pg/mL) followed by subgroup E (463.00 ± 11.09 pg/mL; p = 0.005), with statistically significant differences compared with the other subgroups (p < 0.001). The epitope of subgroup A demonstrated the lowest levels (24.60 ± 3.20 pg/mL) compared with the other subgroups, including the infected control (34.20 ± 1.92 pg/mL; p = 0.025), (Fig. 4a), whereas IL-4 demonstrated contrary results. The highest level of IL-4 was recorded in subgroup A (192.80 ± 2.58 pg/mL), with a statistically significant difference compared with the infected control (120.00 ± 3.80 pg/mL) and other subgroups (p < 0.001). The lowest level was recorded in subgroup C (11.20 ± 1.30 pg/mL) (Fig. 4b).

**Assessment of IgG2a and IgG1 response**

Similar to IFN-γ results, the highest level of Th1-stimulated IgG2a release was detected in subgroup C (0.79 ± 0.008), which showed statistically significant differences compared with the other groups (p < 0.001). The second highest level of IgG2a was found in subgroup E (0.58 ± 0.01). The epitope of subgroup A showed the lowest IgG2a scores (0.05 ± 0.005) (Fig. 4c). Conversely, the Th2-stimulated IgG1 release was

---

**Table 2 Predicted MHC-I and MHC-II epitopes**

| MHC-I epitopes | Antigenicity (threshold 0.5) | Immunogenicity (threshold 0.75) | Allergenicity | Toxicity (threshold 0.75) | MHC-I interaction (affinity of IC50 < 200) | MHC-II epitopes | MHC-II interaction (affinity of IC50 < 1,000) |
|---------------|-----------------------------|-------------------------------|--------------|----------------|--------------------------------|----------------|----------------------------------|
| ARELAWATL     | 0.2611                      | 0.32365                       | Non-allergen | Non-Toxin       | HLA-A*02:50, HLA-A*32:07, HLA-C*03:03, HLA-C*12:03, HLA-B*58:01, HLA-B*15:02, HLA-C*07:02, HLA-A*32:15, HLA-B*57:01, HLA-C*07:01 | NERARELAWATL-LAAD | HLA-DRB1*04:05 |
| KHAGAIAHL     | 0.7                         | 0.2621                        | Non-allergen | Non-Toxin       | HLA-A*02:50, HLA-A*32:07, HLA-A*32:15, HLA-C*12:03, HLA-A*02:17, HLA-B*57:01, HLA-A*02:17 | DPAKHAGAIAHLESE | HLA-DQA1*01:02, HLA-DQB1*06:02 |
| LLRRLIVTK     | 0.496                       | 0.24088                       | Non-allergen | Non-Toxin       | HLA-A*32:07, HLA-C*12:03, HLA-A*31:01, HLA-A*01:01 | TQHPVLLRRLIVTKE | HLA-DRB1*04:05, HLA-DRB1*08:02, HLA-DRB1*04:01 |

---

**Effects of epitopes on levels of IFN-γ and IL-4**

In contrast to the parasite burden, the highest level of IFN-γ was recorded in subgroup C (517.60 ± 3.64 pg/mL) followed by subgroup E (463.00 ± 11.09 pg/mL; p = 0.005), with statistically significant differences compared with the other subgroups (p < 0.001). The epitope of subgroup A demonstrated the lowest levels (24.60 ± 3.20 pg/mL) compared with the other subgroups, including the infected control (34.20 ± 1.92 pg/mL; p = 0.025), (Fig. 4a), whereas IL-4 demonstrated contrary results. The highest level of IL-4 was recorded in subgroup A (192.80 ± 2.58 pg/mL), with a statistically significant difference compared with the infected control (120.00 ± 3.80 pg/mL) and other subgroups (p < 0.001). The lowest level was recorded in subgroup C (11.20 ± 1.30 pg/mL) (Fig. 4b).

**Assessment of IgG2a and IgG1 response**

Similar to IFN-γ results, the highest level of Th1-stimulated IgG2a release was detected in subgroup C (0.79 ± 0.008), which showed statistically significant differences compared with the other groups (p < 0.001). The second highest level of IgG2a was found in subgroup E (0.58 ± 0.01). The epitope of subgroup A showed the lowest IgG2a scores (0.05 ± 0.005) (Fig. 4c). Conversely, the Th2-stimulated IgG1 release was
In this study, we aimed to evaluate peptide epitopes as vaccine candidates for CL—the most common form of leishmaniasis—for which there is no licensed vaccine. Because the chemotherapeutics used are toxic and infected patients in nonendemic areas are usually undiagnosed until irreversible scar formation, vaccination is the logical step to control this disfiguring disease.

In the past, leishmanization was widely used for many years in the Middle East as an effective way of vaccination. The high efficacy of this method is due to its similarity with natural infection that usually ends with a lifelong immunity to reinfection. It is practiced through intradermal inoculation of the virulent strain of *L. major* in hidden parts of the skin. The lifelong immunity that follows healing prevents the appearance of disfiguring scars on the face if reinfection occurs. However, it is no longer practiced due to safety and ethical issues, e.g., exacerbation and delayed healing of lesions at the site of inoculation occurred in some leishmanized individuals (Huang et al. 2015; Pacheco-Fernandez et al. 2021).

In addition to avoiding the hazards of live vaccines, the various advantages of peptide epitopes versus other vaccine candidates (Herrera-Najera et al. 2009) prompted us to perform this study. We selected peptides from *L. major* calpain because they are important for the survival and virulence of *Leishmania*. Such proteins stimulate potent immune responses and are a good choice as a vaccine candidate. Studies in which drugs targeted calpains achieved good therapeutic results (Ennes-Vidal et al. 2017; De Souza Araujo et al. 2018). Moreover, satisfactory results were reported when these were used as vaccine candidates in other organisms, e.g., *Schistosoma* (Rojo et al. 2017; Siddiqui and Siddiqui 2017). Because the immunogenicity of epitopes is generally lower than total protein antigens, its adsorption to an adjuvant is important to increase its antigenicity. We used Imject Alum as an adjuvant to benefit from its depot criterion. It binds strongly with the

**Discussion**

The highest in subgroup A (0.85 ± 0.01) (*p* < 0.001 for all groups) and lowest in subgroup C (0.02 ± 0.004) (Fig. 4d).
antigen, retaining it at the injection site for slower and continuous release (Raman et al. 2012; Ghimire 2015).

In silico prediction of calpain epitopes showed that, of the 203 predicted T-cell epitopes, strong affinities were exhibited by three highly antigenic, immunogenic, and highly conserved CD8$^+$ T-cell epitopes (ARELAWATL, KHAGAIHL, and LLRRLIVTK) and three CD4$^+$ T-cell epitopes (NERARELAWATLAAD, DPAKHAGAIHL-EE, and TQHPVLLRLIVTKE). Ochoa et al. (2019) reported that MHC-II molecules respond against extracellular proteins, in particular, small peptides to which they bind to activate the immune system.

Immunization with the TQHPVLLRLIVTKE and KHAGAIHL calpain epitopes induced TCM cell formation, which resulted in a potent stimulation of the protective Th1 immune response after L. major challenge. In a previous study, in silico predicted SARS-CoV-2 peptides were used individually or in combination to immunize female Balb/c mice. The immunized mice raised reactive antibodies against two out of six SARS-CoV-2 short peptides (Shehata et al. 2021).

The epitopes we designed were not restricted to CD4$^+$ lymphocyte-directed epitopes. We developed CD8$^+$ lymphocyte-directed epitopes because they are also crucial in preventing the spread of L. major infection and healing of lesions (Belkaid et al. 2002). Bioinformatics analyses of immunogenic T-cell epitopes of LeIF and PpSP15 proteins from L. major and sand fly saliva were used as model antigens to design a multiepitope vaccine for leishmaniasis. A complete set of 9-mer MHC-I and 15-mer MHC-II peptides was identified with a high affinity for antigenic epitopes that induce specific responses of CD8$^+$ and CD4$^+$ T-cells in BALB/c mice and humans (Bordbar et al. 2020). Salehi-Sangani et al. (2019) designed a multivalent DNA vaccine encoding the most immunogenic regions of L. major antigens, including
thiol-specific antioxidant protein, *L. major* stress-inducible protein 1, *Leishmania* homologue of receptors for activated C kinase, and kinetoplastid membrane protein-11 in BALB/c mice. Although the DNA vaccine obtained from the immunogenic chimeric protein of *L. major* antigens could induce a high level of IFN-γ production, it protected mice against *L. major* partially.

We chose BALB/c mice as our animal model because of their natural genetic susceptibility to *L. major* infection. This strain lacks the ability to produce IL-12, which directs the immune response toward the protective Th1 lymphocytes; however, it develops the IL4-induced Th2 lymphocytes faster than resistant strains, causing progressive skin lesions and sometimes visceral invasion (Güler et al. 1996; von Stebut and Udey 2004). Thus, any degree of protection detected against the test epitopes was not the animal’s natural resistance to infection.

Healing in leishmaniasis depends on the generation of CD4+ Th1 cells, which produce IFN-γ, with subsequent activation of macrophages to kill intracellular parasites. This pathway ends with the formation of short-lived effector T-cells and long-lived central memory T-cells and skin-resident memory T-cells which are responsible for immunity to secondary infections. Therefore, a successful vaccine must induce long-lived memory T-cell formation that can be maintained without the continued presence of parasites (Glennie and Scott 2016).

We focused on TCM cells because among different memory cell types, TCM cells are responsible for mediating long-term immunity against *L. major* even in the absence of parasites (Zaph et al. 2004). The CD4+ TCM cell type was chosen because it is crucial for the generation of functional and protective antigen-specific CD8+ T-cells and B-cells in addition to the protective Th1 cells (MacLeod et al. 2010). This could explain the marked increase in Th1 biomarkers (i.e., IFN-γ and IgG2a) in subgroups C and E, which had the highest percentages of TCM cells. The role of epitope-induced TCM cells was confirmed in subgroup A. This group scored the least TCM percentage and the lowest levels of IFN-γ and IgG2a. Contrarily, the levels of Th2 biomarkers (IL-4 and IgG1) in subgroup A were the highest among all groups. Thus, in absence of TCM cells, the epitope of subgroup A could not change the immunologic nature of BALB/c mice.

The predominant Th1 response, which was highest in subgroup C, can explain the marked reduction of parasite
density in this subgroup. The high serum levels of IFN-γ secreted by Th1 lymphocytes, macrophages, and other immune cells are a well-known factor for resistance to Leishmania infection. We selected IFN-γ as the primary marker of activated Th1 response because it promotes IL-12 secretion and Th1 activation. Th1 cells reciprocally secrete IFN-γ in more significant amounts promoting macrophage activation at the lesion site, which in turn kills the intracellular Leishmania in a nitric oxide-dependent manner (Vanloubbeeck and Jones 2004; Scott and Novais 2016). Moreover, IFN-γ induces differentiation of CD8+ lymphocytes, which in turn secrete more IFN-γ. Due to similar IFN-dependent killing mechanisms (Uzonna et al. 2004), CD8+ lymphocytes should have contributed to parasite density reduction, especially in the subgroups immunized with the CD8+ targeting epitopes, e.g., subgroup E, which ranked second to subgroup C.

The humoral immune response of subgroup C was also of the protective type, IgG2a (Doroud et al. 2011). Shifting of the IgG2a/IgG1 ratio toward the IgG2a isotype is associated with a protective immune response because reduced IgG1 levels means lower IL-10 production from macrophages, and subsequently, reduced pathology and tissue damage (Miles et al. 2005; Rostamian et al. 2017). This can explain the reduced lesion size in this subgroup. The combination of TCM cells, protective Th1 lymphocytes, and IgG2a stimulation induced by the epitope of subgroup C meets the criteria for a good vaccine candidate (Pérez-Jiménez et al. 2006).

Because opposites make things manifest, the scores detected in the subgroup A, which showed the lowest percentages of TCM cells, showed importance of TCM cells. The marked predominance of the Th2 response, which increases pathology, was associated with the highest parasitic burden and skin lesion number in subgroup A compared with subgroup C. The elevation in IL-4 levels is a hallmark of the Th2 response. It drives Th0 differentiation toward the Th2 type and suppresses the development of Th1 lymphocytes. Elevated levels of IL-4 correlate positively with nonhealing and severity of L. major infection (Kropf et al. 2003; Poudel et al. 2020). Moreover, the increase in the IgG1 isotype may have contributed to this subgroup’s high parasite burden and impaired healing (Miles et al. 2005; Rostamian et al. 2017).

To our knowledge, this is the first published study to investigate calpain peptides as vaccine candidates for L. major. However, a calpain-based vaccine, against Sm-p80 protein, was used against Schistosoma mansoni infection and could stimulate both cellular and humoral immune responses with Th1 lymphocyte predominance (Rojo et al. 2017; Siddiqui and Siddiqui 2017). These findings are consistent with ours. Based on our findings, the CD8+ lymphocyte-directed peptides demonstrated varying degrees of protection against L. major infection, which can be attributed to their ability to induce the formation of protective CD8+ lymphocytes that secret IFN-γ. These cells subsequently killed L. major, reduced parasite burden, and stimulated Th1 lymphocytes to kill more Leishmania and limit the tissue-damaging immune response, which is a vicious circle similar to that reported by Uzonna et al. (2004). Protection against L. major infection can also be attributed to the presence of TCM cells, which markedly increased in number in subgroup E and are crucial for the proliferation of CD8+ lymphocytes (MacLeod et al. 2010).

The absence of complete clearance of parasites with our epitopes is not a defect. The low levels of parasites are not pathological but stimulate effector and memory cells, which prevent incidence of harmful sequelae on exposure to second infection. This is a goal of an effective vaccine candidate (Glennie and Scott 2016).

Conclusion

Our findings reveal that the calpain peptide epitopes TQHPVLLRLIVTKE and KHAGAI AHL directed toward CD4+ and CD8+ lymphocytes, respectively, provided the best protection against L. major infection. They upregulated TCM lymphocytes, and subsequently, the protective Th1 response and its biomarkers (i.e., IFN-γ and IgG2a) while downregulating the pathogenic Th2 lymphocytes. This is a pilot study that identifies calpain peptides as potential vaccine candidates because they meet important criteria, control infection, and generate memory cells.

Limitations of the study

Our study has some limitations. First, the absence of a licensed vaccine prevents us from comparing our results with the designed epitopes with that of the vaccine. Second, more cytokines and immune markers, e.g., IL-10, must be assessed to give a precise view of the resultant immune response.

Author contribution RB and SS contributed equally to this work. Both authors shared in conceptualizing and design of the work; immunization and challenging of mice, the acquisition, and interpretation of data; manuscript writing and revision. AM, design of the calpain epitopes. EAEG, quantitation of parasitic burden using RT-PCR and flowcytometry. SS, analysis of results. RB, AM, EAEG, SS and SS, revision of the manuscript.
Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Data availability All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Declarations

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E, Bertholet S, Udey MC, Sacks D (2002) CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168(8):3992–4000. https://doi.org/10.4049/jimmunol.168.8.3992

Belkhlifa-Slimani R, Djerdjouri B (2018) Caffeic acid combined with autoclaved Leishmania major boosted the protection of infected BALB/c mice by enhancing IgG2 production, IFN-γ/IL-12 responses and in vivo immunity against Leishmania major infection. J Mol Biol 477(2):154–162. https://doi.org/10.1016/j.jmb.2018.01.011

Dimitrov I, Bangov I, Flower DR, Doytchinova I (2014a) AllerTOP vol 2—a server for in silico prediction of allergens. J Mol Model 20(6):2278. https://doi.org/10.1007/s00894-014-2278-5

Dimitrov I, Naneva L, Doytchinova I, Bangov I (2014b) AllergenFP: allergenicity prediction by descriptor fingerprints. Bioinformatics 30(6):846–851. https://doi.org/10.1093/bioinformatics/bt4619

De Souza Araújo PS, de Oliveira SSC, d’Avila-Levy CM, dos Santos ALS, Branquinha MH (2018) Susceptibility of promastigotes and intracellular amastigotes from distinct Leishmania species to the calpain inhibitor MDL28170. Parasitol Res 117:2085–2094. https://doi.org/10.1007/s00436-018-5894-7

De Brito RCF, Cardoso JMO, Reis LES et al (2018) Peptide Vaccines for Leishmaniasis Front 9:1043. https://doi.org/10.3389/fimmu.2018.01043

Doroud D, ZahediFard F, Vatanara A, Najafabadi AR, Tashlizi Y, Vahabpour R, Torkashvand F, Vaziri B, Rafati S (2011) Delivery of a cocktail DNA vaccine encoding cytotoxic proteins of type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release 153(2):154–162. https://doi.org/10.1016/j.jconrel.2011.04.011

Doytchinova IA, Flower DR (2007) VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics 8:4. http://www.biomedcentral.com/1471-2105/8/4

Ennes-Vidal V, Menna-Barreto RFS, Branquinha MH, Dos Santos ALS, d’Avila-Levy CM (2017) Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis? Parasitol 144(2):117–123. https://doi.org/10.1016/j.parasitology.2016.01.009

Ersfeld K, Barraclough H, Gull K (2005) Evolutionary relationships and protein domain architecture in an expanded calpain superfamily in kinetoplastid parasites. J Mol Evol 61(6):742–757. https://doi.org/10.1007/s00239-004-0272-8

Gershoni JM, Roitburd-Berman A, Siman-Tov D, Tarnovitski-Freund N, Weiss Y (2007) Epitope mapping: the first step in developing epitope-based vaccines. Biodrugs 21(3):145–156. https://doi.org/10.2165/00036030-200721030-00002

Ghirmire TR (2015) The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo Paradigm. Springer plus 4:181. https://doi.org/10.1186/s40064-015-0972-

Glennie ND, Scott P (2016) Memory T cells in cutaneous leishmaniasis. Cell Immunol 309:50–634. https://doi.org/10.1016/j.cellimm.2016.07.010

Güler ML, Gorham JD, Hsieh CS, Mackey AJ, Steen RG, Dietrich WF, Murphy KM (1996) Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development. Science 271(5251):984–987. https://doi.org/10.1126/science.271.5251.984

Huang L, Hinman M, Mendez S (2015) Coinjection with TLR2 agonists reduces the pathology of leishmanization in mice. PLoS Negl Trop Dis 9:4: e0003546. https://doi.org/10.1371/journal.pntd.0003546
Jespersen MC, Peters B, Nielsen M, Marcatili P (2017) BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res 45(W1): W24-W29. https://doi.org/10.1093/nar/gkx346

Kaye PM, Picado A, Van Bocxlaer K, Croft SL (2020) Leishmaniasis immunopathology impact on design and use of vaccines, diagnostics and drugs. Semin Immunopathol 42:247–264. https://doi.org/10.1007/s00281-020-00788-y

Kropf P, Herath S, Weber V, Modelell M, Müller I (2003) Factors influencing Leishmania major infection in IL-4-deficient BALB/c mice. Parasite Immunol 25(8–9):439–447. https://doi.org/10.1111/j.1365-3024.2003.00655.x

Kumar V, Ahmad A (2017) Targeting calpain: a novel immunomodulatory approach for microbial infections. Eur J Pharmacol 814:28–44. https://doi.org/10.1016/j.ejphar.2017.08.002

Li CK, Wu H, Yan H et al (2008) T cell responses to whole SARS coronavirus in humans. J Immunol 181:5490–5500. https://doi.org/10.4049/jimmunol.181.8.5490

MacLeod MK, Kappler JW, Marrack P (2010) Memory CD4 T cells: generation, reactivation and re-assignment. Immunol 130(1):10–15. https://doi.org/10.1111/j.1365-2657.2010.03260.x

Miles SA, Conrad SM, Alves RG, Jeronimo SM, Mosser DM (2005) A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 201(5):747–754. https://doi.org/10.1084/jem.20041470

Ochoa R, Laio A, and Cossio P (2019) Predicting the affinity of peptides to major histocompatibility complex class II by scoring molecular dynamics simulations. J Chem Inf Model 59:3464–3473. https://doi.org/10.1021/acs.jcim.9b00403

Pacheco-Fernandez T, Volpedo G, Gnavarama S, Bhattacharya P, Dey R, Satoskar A, Matlashewski G, Nakhlas HI (2021) Revival of Leishmanization and Leishmanin. Front Cell Infect Microbiol 11:639801. https://doi.org/10.3389/fcimb.2021.639801

Pérez-Jiménez E, Kochan G, Gherardi MM, Esteban M (2006) MVA-LACK as a safe and efficient vector for Leishmania major vaccines. Microbes Infect 8(3):810–822. https://doi.org/10.1016/j.micinf.2005.10.004

Poudel B, Yorek MS, Mazgaen L, Brown SA, Kaneganta TD, Gurung P (2020) Acute IL-4 governs pathogenic T cell responses during Leishmania major Infection. Immunohorizons 4(9):546–560. https://doi.org/10.4049/immunohorizons.0000076

Rabienia M, Roudbari Z, Ghanbariasad A, Abdollahi A, Mohamadi E, Mortazavidehkordi N, Farjadfar A (2020) Exploring membrane proteins of Leishmania major to design a new multiple epitope vaccine using immunoinformatics approach. Eur J Pharm Sci 152:105423. https://doi.org/10.1016/j.ejps.2020.105423

Raman VS, Duthie MS, Fox CB, Matlashewski G, Reed SG (2012) Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol 3:144. https://doi.org/10.3389/fimmu.2012.00144

Rojo JU, Melkus MW, Kottapalli KR, Okiya OE, Sudduth J, Zhang W, Molehin AJ, Carter D, Siddiqui AA (2017) Sm-p80-based schistosomiasis vaccine mediated epistatic interactions identified potential immune signatures for vaccine efficacy in mice and baboons. PLoS ONE 12:e0171677. https://doi.org/10.1371/journal.pone.0171677

Rostamian M, Sohrabi S, KavosiFarid H, Niknam HM (2017) Lower levels of IgG1 in comparison with IgG2a are associated with protective immunity against Leishmania tropica infection in BALB/c mice. J Microbiol Immunol Infect 50(2):160–166. https://doi.org/10.1016/j.jmii.2015.05.007

Salehi-Sangani Gh, Mohebali M, Jajarmi V, Khamesipour A, Bandepour M, Mahmoudi M, Zahedi-Zavaram H (2019) Immunization against Leishmania major infection in BALB/c mice using a subunit-based DNA vaccine derived from TSA, LmSTI1, KMP11, and LACK predominant antigens. Iran J Basic Med Sci 22:1493–1501. https://doi.org/10.22038/ijbms.2019.14051

Scott P, Novais FO (2016) Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol 16(9):581–592. https://doi.org/10.1038/nri.2016.72

Shehata MM, Mahmoud SH, Tarek M, Al-Karmalawy AA, Mahmoud A, Mostafa AM, Elhefnawi A, Ali MA (2021) In silico and in vivo evaluation of SARS-CoV-2 predicted epitopes-based candidate vaccine. Molecules 26:6182. https://doi.org/10.3390/molecules26206182

Shermeh AS, Zahedifard F, Habibzadeh S, Taheri T, Rafati S, Seyed N (2021) Evaluation of protection induced by in vitro maturated BMDCs presenting CD8+ T cell stimulating peptides after a heterologous vaccination regimen in BALB/c model against Leishmania major. Exp Parasitol 223:108082. https://doi.org/10.1016/j.exppara.2021.108082

Siddiqui AA, Siddiqui SZ (2017) Sm-p80-based schistosomiasis vaccine: preparation for human clinical trials. Trends Parasitol 33:194–201. https://doi.org/10.1016/j.pt.2016.10.010

Singh H, Ansari HR, Raghava GP (2013) Improved method for linear B-cell epitope prediction using antigen’s primary sequence. PLoS ONE 8(5):e62216. https://doi.org/10.1371/journal.pone.0062216

Skwarczynski M, Toth I (2016) Peptide-Based Synthetic Vaccines. Chem Sci 7(2):842–854. https://doi.org/10.1039/C5CS03892H

Solana JC, Ramírez L, Corvo L, de Oliveira CI, Barral-Netto M, Requena JM, Iborra S, Soto M (2017) Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models. PLoS Negl Trop Dis 11(5): e0005644. https://doi.org/10.1371/journal.pntd.0005644

Spitzer N, Jardim A, Lippert D, Olafson RW (1999) Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine 17(11–12):1298–1300. https://doi.org/10.1016/S0264-410X(98)00363-6

Tupperwar N, Vinceth V, Rath S, Vaidya T (2008) Development of a real-time polymerase chain reaction assay for the quantification of Leishmania species and the monitoring of systemic distribution of the pathogen. Diagn Microbiol Infect Dis 61(1):23–30. https://doi.org/10.1016/j.diagmicrobio.2007.12.013

Uzonna JE, Joyce KL, Scott P (2004) Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon gamma-producing CD8+ T cells. J Exp Med 199(11):1559–1566. https://doi.org/10.1084/jem.20040172

Vambergueck Y, Jones DE (2004) The immunology of Leishmania infection and the implications for vaccine development. Ann N Y Acad Sci 1026:267–272. https://doi.org/10.1196/annals.1307.041

von Stebut E, Udey MC (2004) Requirements for Th1-dependent immunity against infection with Leishmania major. Microbes Infect 6(12):1102–1109. https://doi.org/10.1016/j.micinf.2004.05.024

Zaph C, Uzonna J, Beverley SM, Scott P (2004) Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med 10(10):1104–1110. https://doi.org/10.1038/nm1108

Zhang W, Karmakar S, Gnavavarama S et al (2020) A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISP/R gene editing. Nat Commun 11:3461. https://doi.org/10.1038/s41467-020-17154-z

Zhang X, Li XC, Xiao X, Sun R, Tian Z, Wei H (2013) CD4+ CD62L+ central memory T cells can be converted to Foxp3(+) T cells. PLoS ONE 8(10):e77322. https://doi.org/10.1371/journal.pone.0077322

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.